Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1992 2
1993 1
1994 3
1995 4
1996 1
1998 1
1999 5
2000 5
2001 1
2002 1
2003 5
2004 3
2005 4
2006 1
2007 4
2008 3
2009 1
2010 2
2011 4
2012 3
2013 1
2014 2
2015 4
2016 4
2017 3
2018 2
2019 3
2021 6
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
G2E3 attenuating replicative stress.
Schmidt F, Karnitz LM, Dobbelstein M. Schmidt F, et al. Among authors: karnitz lm. Aging (Albany NY). 2015 Aug;7(8):527-8. doi: 10.18632/aging.100784. Aging (Albany NY). 2015. PMID: 26298869 Free PMC article. No abstract available.
Cytokine receptor signaling mechanisms.
Karnitz LM, Abraham RT. Karnitz LM, et al. Curr Opin Immunol. 1995 Jun;7(3):320-6. doi: 10.1016/0952-7915(95)80105-7. Curr Opin Immunol. 1995. PMID: 7546395 Review.
Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM, Zou L. Karnitz LM, et al. Clin Cancer Res. 2015 Nov 1;21(21):4780-5. doi: 10.1158/1078-0432.CCR-15-0479. Epub 2015 Sep 11. Clin Cancer Res. 2015. PMID: 26362996 Free PMC article. Review.
CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia.
Ding H, Vincelette ND, McGehee CD, Kohorst MA, Koh BD, Venkatachalam A, Meng XW, Schneider PA, Flatten KS, Peterson KL, Correia C, Lee SH, Patnaik M, Webster JA, Ghiaur G, Smith BD, Karp JE, Pratz KW, Li H, Karnitz LM, Kaufmann SH. Ding H, et al. Among authors: karnitz lm. Cancer Res. 2021 May 15;81(10):2666-2678. doi: 10.1158/0008-5472.CAN-20-1504. Epub 2021 Jan 7. Cancer Res. 2021. PMID: 33414171 Free PMC article.
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Huang D, et al. Among authors: karnitz lm. Cell Rep Med. 2021 Dec 21;2(12):100471. doi: 10.1016/j.xcrm.2021.100471. eCollection 2021 Dec 21. Cell Rep Med. 2021. PMID: 35028612 Free PMC article.
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
Hurley RM, McGehee CD, Nesic K, Correia C, Weiskittel TM, Kelly RL, Venkatachalam A, Hou X, Pathoulas NM, Meng XW, Kondrashova O, Radke MR, Schneider PA, Flatten KS, Peterson KL, Becker MA, Wong EM, Southey MS, Dobrovic A, Lin KK, Harding TC, McNeish I, Ross CA, Wagner JM, Wakefield MJ, Scott CL, Haluska P, Wahner Hendrickson AE, Karnitz LM, Swisher EM, Li H, Weroha SJ, Kaufmann SH. Hurley RM, et al. Among authors: karnitz lm. NAR Cancer. 2021 Jul 9;3(3):zcab028. doi: 10.1093/narcan/zcab028. eCollection 2021 Sep. NAR Cancer. 2021. PMID: 34316715 Free PMC article.
75 results